Integrating Therapeutic Advances and Value-Based Models in Myasthenia Gravis Management

Program Description

Generalized myasthenia gravis (gMG) is a chronic autoimmune disorder in which autoantibodies disrupt communication between nerves and muscles. This disruption leads to fluctuating muscle weakness that can severely impair vision, speech, swallowing, and respiratory function. Many patients experience unpredictable cycles of physical decline and fatigue that reduce independence, with approximately 15% of patients remaining refractory to standard treatments and at increased risk of life-threatening myasthenic crises. While traditional management relies on acetylcholinesterase inhibitors, corticosteroids, and non-steroidal immunosuppressants, the therapeutic landscape is shifting toward targeted biologics, including neonatal Fc receptor (FcRn) blockers and complement (C5) inhibitors. These newer therapies offer potentially improved disease control by interrupting key immune pathways, yet their integration is hindered by high costs, complex adverse effect management, and insurance coverage barriers. Managed care pharmacists are pivotal in navigating these challenges by developing utilization management strategies, implementing value-based care models, and coordinating multidisciplinary care to ensure sustainable access to specialty agents. This session features expert-led discussion on the latest clinical data and best practices to assess emerging therapies and apply value-based strategies, empowering managed care professionals to optimize patient-specific treatment decisions and improve long-term clinical and economic outcomes for those living with gMG.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: April 30, 2026
Expiration date: April 30, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

• Apply knowledge of generalized myasthenia gravis (gMG) clinical features, symptom patterns, and disease burden to guide patient-specific treatment decisions.
• Employ gMG management protocols and emerging therapies to select treatments that target disease-driving mechanisms.
• Examine the economic burden of gMG to implement value-based strategies that guide utilization management of novel therapies.